9548378|t|Apomorphine-induced hypoattention in rats and reversal of the choice performance impairment by aniracetam.
9548378|a|Aging-, disease- and medication-related imbalance of central dopaminergic neurons causes functional impairment of cognition and neuropsychological delirium in humans. We attempted to develop a new delirium model using the direct dopamine agonist, apomorphine, and a choice reaction performance task performed by middle-aged rats. The psychological properties of the model were assessed by determining behavioral measures such as choice reaction time, % correct and % omission. Apomorphine (0.03-0.3 mg/kg s.c.) produced a dose-dependent impairment of task performance. The dose of 0.1 mg/kg prolonged choice reaction time, decreased % correct and increased % omission, indicating that rats had attentional deficits and a reduced arousal or vigilance but no motor deficits or reduced food motivation. This psychological and behavioral impairment of performance resembled that of clinically defined delirium. In this model, the cholinomimetic, aniracetam (10 mg/kg p.o.), reversed the performance impairment induced by apomorphine. Its two metabolites, 2-pyrrolidinone (10 and 30 mg/kg p.o.) and N-anisoyl-gamma-aminobutyric acid (GABA, 10 mg/kg p.o.), effectively reversed the performance impairment as the intact drug did. Another pyrrolidinone derivative, nefiracetam (10 and 30 mg/kg p.o.), tended to worsen the apomorphine effect. The cholinesterase inhibitor, tacrine (10 mg/kg p.o.), markedly worsened all of the behavioral measures. Neuroleptics, haloperidol (0.025 mg/kg s.c.), tiapride (30 mg/kg p.o.) and sulpiride (10 and 30 mg/kg p.o.), antagonized the apomorphine effect. The present results suggest that apomorphine-induced behavioral disturbances in the choice reaction performance task seems to be a useful delirium model and aniracetam may improve delirium through the action of 2-pyrrolidinone and N-anisoyl-GABA, presumably by facilitating dopamine release in the striatum by acting as an AMPA or metabotropic glutamate receptor agonist.
9548378	0	11	Apomorphine	Chemical	MESH:D001058
9548378	20	33	hypoattention	Disease	
9548378	37	41	rats	Species	10116
9548378	95	105	aniracetam	Chemical	MESH:C036466
9548378	196	230	functional impairment of cognition	Disease	MESH:D003072
9548378	235	262	neuropsychological delirium	Disease	MESH:D003693
9548378	266	272	humans	Species	9606
9548378	304	312	delirium	Disease	MESH:D003693
9548378	336	344	dopamine	Chemical	MESH:D004298
9548378	354	365	apomorphine	Chemical	MESH:D001058
9548378	431	435	rats	Species	10116
9548378	584	595	Apomorphine	Chemical	MESH:D001058
9548378	792	796	rats	Species	10116
9548378	801	821	attentional deficits	Disease	MESH:D001289
9548378	836	843	arousal	Disease	MESH:D020921
9548378	864	878	motor deficits	Disease	MESH:D009461
9548378	912	954	psychological and behavioral impairment of	Disease	MESH:D000067073
9548378	1004	1012	delirium	Disease	MESH:D003693
9548378	1049	1059	aniracetam	Chemical	MESH:C036466
9548378	1124	1135	apomorphine	Chemical	MESH:D001058
9548378	1158	1173	2-pyrrolidinone	Chemical	MESH:C028537
9548378	1201	1234	N-anisoyl-gamma-aminobutyric acid	Chemical	-
9548378	1236	1240	GABA	Chemical	-
9548378	1338	1351	pyrrolidinone	Chemical	MESH:D011760
9548378	1364	1375	nefiracetam	Chemical	MESH:C058876
9548378	1421	1432	apomorphine	Chemical	MESH:D001058
9548378	1445	1459	cholinesterase	Gene	65036
9548378	1471	1478	tacrine	Chemical	MESH:D013619
9548378	1560	1571	haloperidol	Chemical	MESH:D006220
9548378	1592	1600	tiapride	Chemical	MESH:D063325
9548378	1621	1630	sulpiride	Chemical	MESH:D013469
9548378	1671	1682	apomorphine	Chemical	MESH:D001058
9548378	1724	1735	apomorphine	Chemical	MESH:D001058
9548378	1744	1767	behavioral disturbances	Disease	MESH:D001523
9548378	1829	1837	delirium	Disease	MESH:D003693
9548378	1848	1858	aniracetam	Chemical	MESH:C036466
9548378	1871	1879	delirium	Disease	MESH:D003693
9548378	1902	1917	2-pyrrolidinone	Chemical	MESH:C028537
9548378	1922	1936	N-anisoyl-GABA	Chemical	-
9548378	1965	1973	dopamine	Chemical	MESH:D004298
9548378	2014	2018	AMPA	Chemical	MESH:D018350
9548378	Positive_Correlation	MESH:D001058	MESH:D004298
9548378	Negative_Correlation	MESH:D001058	MESH:D006220
9548378	Positive_Correlation	MESH:D001058	MESH:D003693
9548378	Negative_Correlation	MESH:C028537	MESH:D003693
9548378	Negative_Correlation	MESH:D063325	MESH:D001523
9548378	Negative_Correlation	MESH:C036466	MESH:D003693
9548378	Positive_Correlation	MESH:C036466	MESH:D018350
9548378	Negative_Correlation	MESH:D013619	65036
9548378	Positive_Correlation	MESH:D001058	MESH:D001289
9548378	Positive_Correlation	MESH:C058876	MESH:D001058
9548378	Positive_Correlation	MESH:C028537	MESH:D018350
9548378	Negative_Correlation	MESH:D063325	MESH:D003693
9548378	Negative_Correlation	MESH:D001058	MESH:D063325
9548378	Negative_Correlation	MESH:D006220	MESH:D003693
9548378	Positive_Correlation	MESH:D001058	MESH:D001523
9548378	Negative_Correlation	MESH:C036466	MESH:D001058
9548378	Negative_Correlation	MESH:D011760	MESH:D003693
9548378	Negative_Correlation	MESH:D001058	MESH:D013469
9548378	Negative_Correlation	MESH:D013469	MESH:D003693

